Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma
- 19 January 2022
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 126 (3), 430-439
- https://doi.org/10.1038/s41416-021-01648-8
Abstract
Background Targeted sequencing of circulating tumour DNA (ctDNA) is a promising tool to monitor dynamic changes in the variant allele frequencies (VAF) of genomic alterations and predict clinical outcomes in patients with advanced urothelial carcinoma (UC). Methods We performed targeted sequencing of 182 serial ctDNA samples from 53 patients with advanced UC. Results Serial ctDNA-derived metrics predicted the clinical outcomes in patients with advanced UC. Combining serial ctDNA aggregate VAF (aVAF) values with clinical factors, including age, sex, and liver metastasis, improved the performance of prognostic models. An increase of the ctDNA aVAF by ≥1 in serial ctDNA samples predicted disease progression within 6 months in 90% of patients. The majority of patients with aVAFs ≤0.7 in three consecutive ctDNA samples achieved durable clinical responses (≥6 months). Conclusions Serial ctDNA analysis predicts disease progression and enables dynamic monitoring to guide precision medicine in patients with advanced UC.Keywords
This publication has 40 references indexed in Scilit:
- Genomic Alterations in Liquid Biopsies from Patients with Bladder CancerEuropean Urology, 2016
- Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNAPLOS ONE, 2015
- Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug AdministrationClinical Cancer Research, 2015
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesScience Translational Medicine, 2014
- Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based ChemotherapyJNCI Journal of the National Cancer Institute, 2013
- Genome Sequencing Identifies a Basis for Everolimus SensitivityScience, 2012
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Oncomine 3.0: Genes, Pathways, and Networks in a Collection of 18,000 Cancer Gene Expression ProfilesNeoplasia, 2007
- ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining PlatformNeoplasia, 2004
- Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of TherapyJournal of Clinical Oncology, 1999